| Name | Title | Contact Details |
|---|
AgaMatrix is revolutionizing health care. We`ve sold over a million devices, two billion sensors, and we are the first FDA cleared medical device/app that works with iOS. AgaMatrix is an inventor and leader in consumer healthcare technology. With fewer than 150 people, almost 50% in R&D, we develop glucose monitoring and management systems for diabetes. Diabetes related care accounts for 20% of all healthcare spending in the US. Our innovative multidisciplinary technology vision includes iPhone, Android, and web applications supported by a cloud-based, Java back end for data management and exchange between patients and their doctors. Our UI/UX won the prestigious red dot design award. Our proprietary tech platform, protected by 126 granted/pending patents, uses DSP algorithms to double accuracy while reducing cost by 50%. AgaMatrix not only developed the first FDA cleared medical device that connects to an iPhone, but has over a dozen other FDA cleared products, and has sold over 2.5M meters and 3B biosensors. Our products are available in 20,000 retail locations and a worldwide in partnership with Sanofi, the world's largest pharmaceutical company. We`ve been featured by the New York Times and Fast Company, and we work with the world`s largest retailers (Walmart, Kroger, Target) and pharmaceutical companies (Sanofi, Perrigo) to change the way diabetes is treated.
Medstrat is a Downers Grove, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Central Minnesota Diagnostic is a Milaca, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Eppendorf is a Enfield, CT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Bloodstream infection leading to sepsis is responsible for more than half of all deaths in hospitals and is the most expensive condition treated in hospitals. Mortality rate increases 6% every hour from onset. Therefore, it is critical the right antibiotic treatment is determined quickly. Current methodologies require 3 days to determine the effective antibiotic. Specific Diagnostics has developed a new technology that determines the effective antibiotic in less than 1 day. Specific`s Reveal™ instrument and assay are cost effective and labor-saving allowing clinics to readily deploy the Specific Reveal solution. Specific`s unique patented technology leverages a low-cost small molecule sensor (SMS) array, enabling diagnostic products that simplify workflow and speed time-to-answer at low cost. Specific`s system streamlines lab workflow, reduce costs, and substantially shorten the time from sample arrival to selection of effective therapy, saving patients faced with fast-moving and deadly drug-resistant blood infections. Specific and its founders have written almost 60 peer-reviewed publications, detailing the successful demonstration of the SMS array technology. The Company itself has independently authored over 20 scientific publications and conference abstracts detailing the SMS array powered detection, identification and antibiotic susceptibility testing.